BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yusuf AA, Govender MA, Brandenburg JT, Winkler CA. Kidney disease and APOL1. Hum Mol Genet 2021;30:R129-37. [PMID: 33744923 DOI: 10.1093/hmg/ddab024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. [DOI: 10.1038/s41581-022-00616-6] [Reference Citation Analysis]
2 Mayanja R, Kintu C, Diabate O, Soremekun O, Oluwagbemi OO, Wele M, Kalyesubula R, Jjingo D, Chikowore T, Fatumo S. Molecular Dynamic Simulation Reveals Structure Differences in APOL1 Variants and Implication in Pathogenesis of Chronic Kidney Disease. Genes 2022;13:1460. [DOI: 10.3390/genes13081460] [Reference Citation Analysis]
3 Eadon MT, Cavanaugh KL, Orlando LA, Christian D, Chakraborty H, Steen-burrell K, Merrill P, Seo J, Hauser D, Singh R, Beasley CM, Fuloria J, Kitzman H, Parker AS, Ramos M, Ong HH, Elwood EN, Lynch SE, Clermont S, Cicali EJ, Starostik P, Pratt VM, Nguyen KA, Rosenman MB, Calman NS, Robinson M, Nadkarni GN, Madden EB, Kucher N, Volpi S, Dexter PR, Skaar TC, Johnson JA, Cooper-dehoff RM, Horowitz CR. Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. Contemporary Clinical Trials 2022;119:106813. [DOI: 10.1016/j.cct.2022.106813] [Reference Citation Analysis]
4 Caliebe A, Tekola-Ayele F, Darst BF, Wang X, Song YE, Gui J, Sebro RA, Balding DJ, Saad M, Dubé MP; IGES ELSI Committee. Including diverse and admixed populations in genetic epidemiology research. Genet Epidemiol 2022. [PMID: 35842778 DOI: 10.1002/gepi.22492] [Reference Citation Analysis]
5 Nuñez E, Orera I, Carmona-Rodríguez L, Paño JR, Vázquez J, Corrales FJ. Mapping the Serum Proteome of COVID-19 Patients; Guidance for Severity Assessment. Biomedicines 2022;10:1690. [PMID: 35884998 DOI: 10.3390/biomedicines10071690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Drak D, Shamu T, Heron JE, Chimbetete C, Dahwa R, Gracey DM. Renal function and associated mortality risk in adults commencing HIV antiretroviral therapy in Zimbabwe. AIDS 2022;36:631-6. [PMID: 34923518 DOI: 10.1097/QAD.0000000000003153] [Reference Citation Analysis]
7 Kelly DE, Ramdas S, Ma R, Rawlings-goss RA, Grant GR, Ranciaro A, Hirbo JB, Beggs W, Yeager M, Chanock S, Nyambo TB, Omar SA, Meskel DW, Belay G, Li H, Brown CD, Tishkoff SA. The Genetic and Evolutionary Basis of Gene Expression Variation in East Africans.. [DOI: 10.1101/2022.02.16.480765] [Reference Citation Analysis]
8 Kirwin SM, Robbins KM, Vinette KM, Hirata L, Gripp KW, Funanage VL. Molecular Genetic Testing for Kidney Disorders During the COVID-19 Pandemic. Delaware Journal of Public Health 2021;7:24-7. [DOI: 10.32481/djph.2021.12.008] [Reference Citation Analysis]
9 Adamson WE, Noyes H, Cooper A, Beckett-hill G, Ogunsola J, Parekh R, Macleod A. Adverse outcomes in SARS-CoV-2 infections are associated with a combination of variant genotypes at two loci in the APOL1 gene: a UK Biobank study.. [DOI: 10.1101/2021.11.02.21265755] [Reference Citation Analysis]
10 Masimango MI, Jadoul M, Binns-roemer EA, David VA, Sumaili EK, Winkler CA, Limou S. APOL1 Renal Risk Variants and Sickle Cell Trait Associations With Reduced Kidney Function in a Large Congolese Population-Based Study. Kidney International Reports 2021. [DOI: 10.1016/j.ekir.2021.09.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]